Graduate Student First Author on PNAS Paper

Three people standing in front of a research poster. One person is giving the Hook 'em Horns hand gesture.
June 13, 2023
Kimberly J. Long, a Ph.D. candidate in the Dalby Lab in the Division of Chemical Biology and Medicinal Chemistry, was a first author of a recent research paper published in the Proceedings of the National Academy of Sciences (PNAS).

College of Pharmacy Researchers Share Latest Findings on Novel Drug Delivery Technology

Five nasal inhalers with their caps on.
October 31, 2022
Researchers in the lab of Dr. Robert O. (Bill) Williams III, Division Head and Professor of Molecular Pharmaceutics and Drug Delivery at the College of Pharmacy, are advancing an innovative platform technology known as Thin Film Freezing, which could revolutionize administration, distribution and access to both vaccines and therapies.

Faculty Earn State Grants for Cancer Research

A person in a lab.
September 21, 2022
The Cancer Prevention and Research Institute of Texas (CPRIT) has released its grant research funding awards for the upcoming year. All three awarded research projects at The University of Texas at Austin involve College of Pharmacy faculty.

Dalby Earns CPRIT Grant for Drug Delivery Program

A person wearing a mask in a lab.
September 16, 2021
The Cancer Prevention and Research Institute of Texas (CPRIT) recently awarded grants to six faculty members at UT Austin, including the Division of Chemical Biology and Medicinal Chemistry's Kevin Dalby, Ph.D. for his Targeted Therapeutic Drug Discovery and Development Program.

Williams Talks to KXAN About How Thin Film Freezing Can Help Treat COVID Patients

A man wearing glasses.
July 30, 2021
Division Head and Professor of Molecular Pharmaceutics and Drug Delivery Dr. Bill Williams was on KXAN News to talk about promising new data from TFF Pharmaceuticals and Augmenta Bioworks. The companies plan to develop Dr. Williams' thin film freezing technology to better deliver antibody treatment directly to the lungs of COVID patients.

Fight Against Antibiotic-Resistant Bacteria Has a Glowing New Weapon

A 3D representation of the chemical probe as it bridges two zinc molecules
June 2, 2021
Chemistry Assistant Professor Emily Que, Ph.D. and the College of Pharmacy’s Walt Fast, Ph.D. are working together to research new methods to fight against antibiotic resistance. The fluorescent chemical probe developed by Que and Fast may help find a different way to combat resistant bacteria.

TxCORE Research Wins PhRMA Foundation Award

Three people smiling.
April 1, 2021
Three researchers from the College of Pharmacy won an award from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. Leticia R. Moczygemba, Pharm.D., Ph.D., Carolyn M. Brown, Ph.D. and Michael Johnsrud, Ph.D., R.Ph. were awarded $5,000 from the PhRMA Foundation for their proposal to advance racial and ethnic representation in value assessments.

Williams Wants to Turn COVID-19 Vaccine into Powder to Help with Storage and Distribution

A powder in a vial.
November 25, 2020
Molecular Pharmaceutics and Drug Delivery Professor Robert O. (Bill) Williams III, Ph.D. talks to CBS Austin about the potential for his thin film freezing technology to increase the shelf life of COVID-19 vaccines when they become available.

Peppas to Receive Prestigious Oesper Award in Honor of Contributions to Chemistry

A smiling man standing in front of a bookshelf.
November 4, 2020
Nicholas A. Peppas, Sc.D. has been honored with the 2020 Oesper Award from the University of Cincinnati’s Chemistry Department and the Cincinnati Section of the American Chemical Society for his outstanding accomplishments in and contributions to science. The award recognizes his work in biomaterials, drug delivery, bionanotechnology, and nanomaterials.

Inhaled Niclosamide a Potential Effective Antiviral to Treat COVID-19

An infrared image of nasal spray being administered.
September 29, 2020
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.